**Supplementary table 1: Adverse events leading to dolutegravir discontinuation according to treatment group and gender**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **AEs LEADING TO DTG DISCONTINUATION**  [n (% population)] # | | | | | | |
|  | **ART NAÏVE** | | **TE** | | **TOTAL** | |
|  | **Female**  **N=8 (5.0%)** | **Male**  **N=31 (4.0%)** | **Female**  **N=9 (5.2%)** | **Male**  **N=18 (3.1%)** | **Female**  **N=17 (5.1%)** | **Male**  **N=49 (3.6%)** |
| **TOXICITY** |  |  |  |  |  |  |
| * **Neuropsychiatric** | 2 (1.3%) | 18 (2.3%) | 3 (1.7%) | 10 (1.7%) | 5 (1.5%) | 28 (2.1%) |
| * **Gastrointestinal** | 0 (0.0%) | 3 (0.4%) | 6 (3.5%) | 0 (0.0%) | 6 (1.8%) | 3 (0.2%) |
| * **Allergic reactions** | 3 (1.9%) | 6 (0.8%) | 0 (0.0%) | 0 (0.0%) | 3 (0.9%) | 6 (0.4%) |
| * **Hepatic** | 1 (0.6%) | 2 (0.3%) | 0 (0.0%) | 1 (0.2%) | 1 (0.3%) | 3 (0.2%) |
| * **Osteoarticular** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.5%) | 0 (0.0%) | 3 (0.2%) |
| * **Renal** | 0 (0.0%) | 1 (0.1%) | 0 (0.0%) | 2 (0.3%) | 0 (0.0%) | 3 (0.2%) |
| * **Other/Unknown** | 2 (1.3%) | 1 (0.1%) | 0 (0.0%) | 2 (0.3%) | 2 (0.6%) | 3 (0.2%) |
| (notes: ART= antiretroviral therapy; AEs= adverse events; DTG=dolutegravir; TE= treatment-experienced). | | | | | | | |
| # For each patient, only one category of toxicity leading to DTG discontinuation is possible. | | | | | | | |